{"id":36520,"date":"2025-09-22T12:27:51","date_gmt":"2025-09-22T16:27:51","guid":{"rendered":"https:\/\/nephcure.org\/?page_id=36520"},"modified":"2025-12-11T15:24:35","modified_gmt":"2025-12-11T20:24:35","slug":"empaveli-pegcetacoplan","status":"publish","type":"page","link":"https:\/\/nephcure.org\/es\/managing-rkd\/treatment-options\/empaveli-pegcetacoplan\/","title":{"rendered":"EMPAVELI (Pegcetacoplan)"},"content":{"rendered":"
\n
Home<\/a><\/span> \/ Managing RKD<\/a><\/span> \/ Treatment Options<\/a><\/span> \/ EMPAVELI (Pegcetacoplan)<\/span><\/span><\/div>\n\n
\n\n

EMPAVELI (Pegcetacoplan)<\/h1>\n\n\n\n

EMPAVELI was approved by the FDA in July 2025 to treat adults and children (12 years and older) with two rare kidney diseases: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). It works by reducing protein in the urine (proteinuria). <\/p>\n\n\n\n

Medically reviewed by Dr. Kenar D. Jhaveri, MD<\/em><\/p>\n\n<\/div>\n<\/section>\n\n

\n\n
\"\"<\/figure>\n\n\n\n

How does <\/strong>EMPAVELI work?<\/strong><\/h2>\n\n\n\n

EMPAVELI is also the only therapy for these conditions that targets complement protein C3 and its fragment C3b. In C3G and IC-MPGN, the complement pathway can become overactive, and instead of attacking only infection, the complement pathway also attacks and damages kidney cells.  EMPAVELI works by blocking the complement pathway and stopping the disease and damage to the kidney. <\/p>\n\n\n

<\/div>\n\n\n
\"\"<\/figure>\n\n\n\n

How is <\/strong>EMPAVELI administered?<\/strong><\/h2>\n\n\n\n

It is given under the skin twice a week using either the EMPAVELI injector or an infusion pump(subcutaneous). The device to do this is provided by the company. Most patients take it twice a week<\/strong> (about every 3\u20134 days). It can be given using either: <\/p>\n\n\n\n